Abstract

Increasing population mobility and increasing frequency and variety of sexually transmitted infections (STI) are closely linked around the globe. Although all mobile populations are at increased risk for acquiring STIs, international travelers are the focus of this review. Several aspects of travel such as opportunity, isolation, and the desire for unique experiences all enhance the likelihood of casual sexual experiences while abroad. The situational loss of inhibition of travel can be markedly enhanced by alcohol and drugs. Several of the most important elements of the complex interaction between travel and STIs are discussed.

The History of Sex and Travel

Sex and travel have a long and occasionally inglorious shared history. From the Huns and Vikings to the current day, unscrupulous military and paramilitary commanders have used sex to motivate men to march across deserts, row open boats across oceans, and face all manner of other perils. 1 Old sailors’ ballads make it clear that the promise of exotic sex in distant lands contributed to the willingness of young men to sign up for the navy or to serve on whaling vessels. 2 When Captain Cook’s crew discovered that Tahitian women would trade sex for iron nails, guards had to be posted to prevent the boats from being dismantled, plank by rapturous plank. 3 The less humorous consequence of this 17th century meeting of cultures is the subject of this review. Within months of their arrival in Tahiti, half of Cook’s crew had venereal diseases leading him to write that “we will be forever damned by the fact that we brought these diseases to these islands.” Since Cook’s time, there has been a remarkable democratization of travel: exotic itineraries are now accessible to a large majority of those living in the developed world including both genders and the extremes of age. Sex is still sex, however, and many will still do remarkably silly things in its pursuit. As a result, the population at risk of acquiring “exotic” sexually transmitted infections (STI) is steadily increasing. The purpose of the current review is to provide travel medicine practitioners with an up‐to‐date understanding of the complex relationship between sex and travel.

STIs—Global Overview

In the past 20 to 30 years, there has been a remarkable growth in population mobility both within and across national boundaries. The World Travel Organization estimates that ∼700 million people crossed international borders in 2002 for work, study, or pleasure and that traffic in 2003 to 2004 exceeded 1 billion such trips. 4 All mobile populations including business travelers, expatriates, soldiers, and tourists are at increased risk for acquiring STIs. 5–8 The anonymity of travel, the sense of isolation brought on by unfamiliar surroundings, and the desire for unique experiences all encourage travelers to shed social and sexual inhibitions. The risk of acquiring an STI may be enhanced in mobile populations by poor understanding of the global epidemiology of these infections 9 and the means available to mitigate risk. Rates of STIs may also be elevated among migrant and marginalized populations (eg, refugees, internally displaced, street youth), and these populations may be overrepresented among commercial sex workers (CSW) in many countries. 6,9–14 Many of the risk factors for disease acquisition in these vulnerable populations are distinct, however, and will not be addressed in this review.

STIs are among the most common notifiable infections worldwide, and rates are particularly high in many developing countries. In 1990, the WHO estimated the global burden of curable STIs at >250 million cases [syphilis, gonorrhea (GC), chlamydia, and trichomoniasis]. 15 Estimates rose to 333 and 340 million new cases of these infections in 1995 and 1999. 8 The 1999 estimate includes 151 million cases in South/Southeast Asia, 38 million in Latin America, and 69 million in Africa. 16,17 In many developing world countries, these increasing numbers have been fueled by the economic and societal disruption of the human immunodeficiency virus (HIV) pandemic. In sub‐Saharan Africa in particular, there has been an explosive growth in the number of children who have lost one or both parents (∼14–20 million in 2000). 18 In the mid‐1990s, >40,000 street children were thought to live in Nairobi alone where many had been driven to trade sex for food to survive. 19,20 Although HIV, syphilis, and GC are usually in the STI spotlight, more than 20 different infectious agents can be acquired and/or spread by various types of sexual contact 9,21 (eg, vaginal sex, anal sex, oral–genital/oral–anal contact; Table 1). Although the prevalence rates for many of these infectious agents still vary widely by geographic region [eg, human lymphotropic virus (HTLV)‐1, chancroid], changes in migration, immigration, and travel patterns during the past 50 years have ensured that almost any STI can be acquired anywhere in the world. As a result, the risk of acquiring a given STI in any particular setting is best considered in quantitative rather than qualitative terms.

Table 1

Sexually transmitted infections

Viral diseases 
 Hepatitis viruses (HAV, HBV, HCV) 
 HIV‐1/2 
 HSV‐I and HSV‐II 
 HTLV‐1 
 Human papillomavirus 
 Cytomegalovirus 
 Epstein–Barr virus 
 Moluscum contagiosum 
Bacterial diseases 
 Calymmatobacterium granulmatosis  (Granuloma inguinale, donovanosis) 
Chlamydia trachomatis (NGU) 
C trachomatis L1‐3 (LGV) 
Gardnerella vaginalis (bacterial vaginosis) 
Haemophilus ducreyi (chancroid) 
Neisseria gonorrheae (gonorrhea) 
Treponema palidum ( syphilis) 
Fungal diseases 
Histoplasma capsulatum (histoplamosis) 
Parasitic diseases 
Entamoeba histolytica 
Trichimonas vaginalis 
Ectoparasitic diseases 
Phthirus pubis (lice) 
Sarcoptes scabiei (scabies) 
Viral diseases 
 Hepatitis viruses (HAV, HBV, HCV) 
 HIV‐1/2 
 HSV‐I and HSV‐II 
 HTLV‐1 
 Human papillomavirus 
 Cytomegalovirus 
 Epstein–Barr virus 
 Moluscum contagiosum 
Bacterial diseases 
 Calymmatobacterium granulmatosis  (Granuloma inguinale, donovanosis) 
Chlamydia trachomatis (NGU) 
C trachomatis L1‐3 (LGV) 
Gardnerella vaginalis (bacterial vaginosis) 
Haemophilus ducreyi (chancroid) 
Neisseria gonorrheae (gonorrhea) 
Treponema palidum ( syphilis) 
Fungal diseases 
Histoplasma capsulatum (histoplamosis) 
Parasitic diseases 
Entamoeba histolytica 
Trichimonas vaginalis 
Ectoparasitic diseases 
Phthirus pubis (lice) 
Sarcoptes scabiei (scabies) 

Note that any “list” of diseases transmissible by sexual activity is somewhat arbitrary. The actual agents and risks are determined by what types of sexual activities are under consideration. HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; HSV = herpes simplex virus; HIV = human immunodeficiency virus; HTLV = human lymphotropic virus; NGU = nongonococcal urethritis; LGV = lymphogranuloma venereum.

STI Prevalence “Gradients” Between the Developed and Developing Worlds

Although STIs can be encountered anywhere, many are hyperendemic in developing world countries. 9 Prevalence data for most developing world countries are derived largely from ad hoc surveys. Such surveys provide useful estimates but must be interpreted with caution because they may not be representative of the total population 22 (Table 2). On the other hand, surveys that focus on CSW may actually be a good reflection of risk to travelers since individuals in this group are the most likely to engage in sex acts with foreigners. For example, prevalence rates for chlamydia infection in antenatal and family planning clinics range from 1.9% to 12.2% in Latin America, 6% to 13% in African countries, and 5.7% to 26% in South/Southeast Asia. 9 These rates overlap with those reported in many developed countries (2.7%–8%). Estimated prevalence rates for GC range from 5.7% to 17% in sub‐Saharan Africa and 0.1% to 3.5% in Asia and Western Pacific countries. 9 Although the number of reported GC cases actually increased in some European countries during the 1990s, the overall incidence of GC urethritis in the developed world remains quite low (2.5–125 per 100,000). 9 In most developed countries, syphilis incidence rates remained well below 5 per 100,000 through the 1990s. In contrast, there have been striking increases in the reported rates of new syphilis cases during this period in Eastern Europe and the independent states of the former Soviet Union (120–170 per 100,000). The reported seroprevalence of syphilis is generally higher in developing world countries ranging from 3.5% to 8% in South/Southeast Asia and the Western Pacific, 5% to 6% in Latin America, and 2.5% to 17% in sub‐Saharan Africa. 9 Not surprisingly, surveys of CSW in the developing world reveal much higher rates of STIs: 13% to 32% for chlamydia, 11% to 45% for GC, and 5% to 55% for syphilis. 9,32,33 The rates for any curable STI among CSW vary from 5% to 65% in Africa, 20.9% in Brazil, and 0% to 13.6% in Southeast Asia. 32,33 When prevalence rates for the major noncurable viral infections that can be sexually transmitted are included (Table 3), it is obvious that there is no such thing as a “safe” sexual encounter with a CSW [eg, HIV, 5 hepatitis B virus (HBV), 48 hepatitis C virus (HCV), 49,50 HTLV‐I 51 ]. It is certainly worth noting that the presence of one of more STIs can increase the risk of HIV transmission by a factor of 3 to 10 or more. 9

Table 2

Examples of STI prevalence rates in healthy populations in the developing world (% of clinic visits)

Country N Source of subjects GC Syphilis Chlamydia Trichomonas Chancroid Garnerella HIV HBV HSV‐II Genital warts 
Nigeria (2003) 23 230 Antenatal 1.3 1.7 — 7.4 — 3.9 — — — — 
Zimbabwe (1984) 24 175 Prenatal/STI 17.8 — 5.9 25.5 17.8 — — — — 13.7 
Ethiopia (1997) 25 1,907 Family planning and others 56 to 66 35 to 39 61 to 64 — — — — — — 19 to 20 
South Africa (1996) 26 lit rev* Various clinics 5 to 15 16 — — 20 to 49 — 38 to 40 38 to 41 — 
Central African Republic (1999) 27 481 Antenatal 3.1 6.7 6.2 9.9 — 29 12.2 — — — 
Thailand (1998) 28 1,021 Antenatal 0.2 0.5 5.7 — — — 3 to 7 — — — 
India (2002) 29 1,981 Various clinics — — — — — — 1.8 5.3 — — 
Mongolia (1997) 30 pop† Various 1.4 0.3 — 1.6 — — <0.001 — — — 
Brazil (2003) 31 13,986 Antenatal and various — — — — — — — — 43 — 
Country N Source of subjects GC Syphilis Chlamydia Trichomonas Chancroid Garnerella HIV HBV HSV‐II Genital warts 
Nigeria (2003) 23 230 Antenatal 1.3 1.7 — 7.4 — 3.9 — — — — 
Zimbabwe (1984) 24 175 Prenatal/STI 17.8 — 5.9 25.5 17.8 — — — — 13.7 
Ethiopia (1997) 25 1,907 Family planning and others 56 to 66 35 to 39 61 to 64 — — — — — — 19 to 20 
South Africa (1996) 26 lit rev* Various clinics 5 to 15 16 — — 20 to 49 — 38 to 40 38 to 41 — 
Central African Republic (1999) 27 481 Antenatal 3.1 6.7 6.2 9.9 — 29 12.2 — — — 
Thailand (1998) 28 1,021 Antenatal 0.2 0.5 5.7 — — — 3 to 7 — — — 
India (2002) 29 1,981 Various clinics — — — — — — 1.8 5.3 — — 
Mongolia (1997) 30 pop† Various 1.4 0.3 — 1.6 — — <0.001 — — — 
Brazil (2003) 31 13,986 Antenatal and various — — — — — — — — 43 — 

STI = sexually transmitted infections; GC = gonorrhea; HIV = human immunodeficiency virus; HBV = hepatitis B virus; HSV = herpes simplex virus.

*

Literature review.

Population‐based study.

Table 3

Examples of STI prevalence rates in CSWs in the developing world (% of clinic visits)

Country N Source of subjects GC Syphilis Chlamydia Trichomonas Chancroid Gardnerella HIV HBV HPV HCV 
Senegal (1998) 34 374 Female CSW 24.9 29.4 — 46 — — — — — — 
South Africa (1998) 35 145 Female CSW 14.3 42.1 16.3 41.3 — 71 50.3 — — — 
China van den Hoek 01) 36 966 Female CSW 24.9* 29.4 24.9 46 — — — — — — 
Indonesia (1997‐2003) 37–39 1,340 Female CSW 10 to 60 7 to 30 9 to 18 4 to 8 — — 0.5 — 37.7 — 
Bangladesh (1998) 40 286 Female CSW 28* 57.1 28* — — — — — — 
Indonesia (2003) 41 296 Male CSW 4 to 13 43.6 2.4 to 3.8 — — — — — — — 
Venezuela (2003) 42 212 Female CSW — 2 to 4 — — — — 13.8 — — 
Brazil (1997) 43 — Female CSW — — — 1.6 — — — 10.9 — — 
Peru (1993) 44 966 Female CSW — — — — — — 0.3 59.8 — 0.7 
Uruguay (2003) 45 200 Male CSW — — — —  — 21.5 50.5 — 6.5 
DRC (2001) 46 1,144 Female CSW — — — — — — 34.1 — — 6.6 
Argentina (2006) 47 625 Female CSW — 45.7 — — — — 3.2 14.4 — 4.3 
Country N Source of subjects GC Syphilis Chlamydia Trichomonas Chancroid Gardnerella HIV HBV HPV HCV 
Senegal (1998) 34 374 Female CSW 24.9 29.4 — 46 — — — — — — 
South Africa (1998) 35 145 Female CSW 14.3 42.1 16.3 41.3 — 71 50.3 — — — 
China van den Hoek 01) 36 966 Female CSW 24.9* 29.4 24.9 46 — — — — — — 
Indonesia (1997‐2003) 37–39 1,340 Female CSW 10 to 60 7 to 30 9 to 18 4 to 8 — — 0.5 — 37.7 — 
Bangladesh (1998) 40 286 Female CSW 28* 57.1 28* — — — — — — 
Indonesia (2003) 41 296 Male CSW 4 to 13 43.6 2.4 to 3.8 — — — — — — — 
Venezuela (2003) 42 212 Female CSW — 2 to 4 — — — — 13.8 — — 
Brazil (1997) 43 — Female CSW — — — 1.6 — — — 10.9 — — 
Peru (1993) 44 966 Female CSW — — — — — — 0.3 59.8 — 0.7 
Uruguay (2003) 45 200 Male CSW — — — —  — 21.5 50.5 — 6.5 
DRC (2001) 46 1,144 Female CSW — — — — — — 34.1 — — 6.6 
Argentina (2006) 47 625 Female CSW — 45.7 — — — — 3.2 14.4 — 4.3 

CSW = commercial sex workers; STI = sexually transmitted infections; GC = gonorrhea; HIV = human immunodeficiency virus; HBV = hepatitis B virus; HSV = herpes simplex virus.

*

Clinical evidence of cervicitis (either GC or chlamydia).

Emerging Drug Resistance Among STIs

In addition to the higher prevalence rates of STIs in the developing world, a steadily increasing proportion of the infections acquired abroad are resistant to standard antibiotics. 52 Beta lactamase–producing strains of Neisseria gonorrheae (NG) are prevalent in Africa, the Caribbean, and Asia. 53–57 Several studies from Africa and Southeast Asia show that penicillin‐resistant N gonorrheae (PRNG) can occur in ≥50% of isolates. 58–60 In Canada, the rate of PRNG was only 8.7% in 1992, but the isolation of resistant organisms has increased substantially since then (15%–22%). 61 Similar findings have been reported for antibiotic‐resistant NG in many other countries of the industrialized world. 61–65 Low‐level, chromosomally mediated tetracycline resistance is also common among NG isolates in developing world settings, 66 and spectinomycin resistance has begun to appear in some industrialized regions as well. 61,67,68 Fluoroquinolone‐resistant NG, which first appeared in 1992 is most prevalent in the Far East but now occurs around the world including Europe, the United States, and Canada. 69 Antibiotic resistance in Haemophilus ducreyi, the causative agent of chancroid, continues to spread globally: 57 resistance to trimethoprim/sulphonamide combination drugs is now widespread in Southeast Asia (eg, Thailand, Vietnam, Laos, Cambodia). 52,70 Some believe that implementation of antiretroviral programs in the developing world will lead to the development of highly resistant HIV strains. 71–73

Sexual Behavior of Travelers

The sexual attitudes and behaviors of developed world travelers have been extensively studied in the past 10 to 15 years 5,58,59,74–83 and have been recently reviewed. 84 Rates of reported casual sexual experiences (CSE) during travel vary between 5 and 51% (summarized in tabular form by Matteelli and Carosi 81 ). Virtually all these studies have been conducted using questionnaires, and no study achieved a 100% response rate (some as low as 30% 85 ). As a result, the reported figures, high as they may appear, are likely to be underestimates. In an “intention‐to‐have‐sex” study of young Australian males traveling to Thailand, only 34% reported a definite intention not to have sex. 76 As many as 47.5% of unmarried UK residents on vacation in Spain reported a CSE during a 2‐week holiday. 83 The rate of new partner acquisition during this 2‐week period was roughly 12‐fold higher than rates observed in the UK. A study of medical students reported that 32% had CSE while on holiday with a mean of three new partners. 86

Although early studies demonstrated that men were far more likely than women to have CSE while traveling, 85 more recent studies suggest that male and female travelers are quite similar in their willingness to acquire new partners while abroad. 80,82,86–90 However, both quantitative and qualitative behavioral differences persist between the sexes (eg, number of partners, willingness to pay for sex, consistent condom use, and partner choice). 83 For example, young women tend to choose fellow travelers or expatriates as new sexual partners, while older female travelers and men of all ages tend to seek out local partners. 91,92 While logical to some extent, the young women’s strategy may not fully mitigate the risk since STI prevalence rates in expatriate communities are likely to be intermediate between those of the home and the local indigenous populations. 93,94 As a second example of differences between the sexes, men tend to seek out “unencumbered” sex with CSW during travel while women are more likely to become romantically involved and assist their sex partners to emigrate. 95

Factors that increase the chances that a given individual will engage in sex while traveling include youth, male sex, traveling alone or with a same‐sex group, a history of casual sex or multiple partners at home, repeated visits to the same region, previous STIs, and higher social status. 91,96,97 As with other high‐risk behaviors, there is also considerable evidence that alcohol and drugs contribute to CSE in both men and women. 12,83,87,91,97–102 Even without actually ingesting intoxicants, travel itself seems to be sufficiently intoxicating to encourage CSE in many people. This syndrome of sun, stimulants, and sex has been described as “situational disinhibition.” 103,104

Travelers Who May Be at Particular Risk for Acquiring STIs

Expatriates

Long‐term overseas workers or expatriates are more likely than other types of travelers to engage in sexual activity while abroad. Among 1,080 US Peace Corps volunteers, 60% had at least one CSE (40% of these contacts were with local residents) and only 33% used condoms. 105 Among Belgian men working in Central Africa, 51 and 31% reported extramarital sex with a local woman and with a CSW, respectively. 93 In a study of 1,968 Dutch expatriates working in sub‐Saharan Africa, 31% of males and 13% of females had casual sex with African partners; regular condom use was reported by less than 25% of the participants. 106 A more recent survey of 634 male and 230 female Dutch expatriates revealed that differences between the sexes are narrowing. 107 In this study 41% of men and 31% of women had either casual or regular sex with local residents. Of the men who had CSE, 59% had paid for sex at least once. These figures help to explain why expatriates tend to have STI prevalence “profiles” that are intermediate between those of their countries of origin and their host countries. 93,94,96,107

VFR Travelers

Travelers returning to their countries of origin to visit family and relatives (so‐called VFR travelers) are at high risk for acquiring a number of travel‐related illnesses. 108,109 Although few studies exist that specifically address this issue, VFR travelers are likely to be at particularly high risk for acquiring STIs. Factors that may influence this risk include the choice of setting to solicit sex, 46,110 more intimate contact with the local population and a willingness to use substandard, locally purchased condoms. 111 A recent study of 756 UK residents of African origin found that 43% of the men and 46% of the women had visited their country of origin in the preceding 5 years. New sexual partners were reported by 40% of the men and 21% of the women. 80 A similar study in 408 VFR travelers from the Netherlands returning to either Surinam or the Antilles revealed that 47% of the men and 11% of the women acquired a new sexual partner while overseas. 112

Military Personnel and Seamen

Seamen and military personnel are reported to have high rates of sexual contact with overseas nationals during postings ranging from 45% to 56%. 113–120 Among 1,744 US Navy and Marine corps personnel deployed abroad for 6 months, 49% reported having had sexual contact and 70% of these reported having had multiple partners. 121 In a Dutch study of 2,289 UN peacekeepers in Cambodia between 1992 and 1993, 45% reported CSE with local partners including CSWs. UK troops posted in the tropics report similar rates of CSE with local partners (56.5%) with only 30% reporting consistent condom use. 113 In a “spot check” of 1,028 US male military personnel in 2002, 7.4% reported either a current or recent (3 month) STI. 114 As additional evidence of the equalization of risk between the sexes, a recent survey of 105 US female military recruits suggested that 66% of them were at risk for the acquisition of STIs. 118,122

Men Who Have Sex With Men

Male homosexual travelers are less well studied than their heterosexual peers. However, the available data suggest that men who have sex with men (MSM) are at least as likely to engage in CSE while traveling as heterosexual men. 89,97,123–126 In a Norwegian study, homosexual/bisexual travelers were twice as likely to have paid for sex while overseas as heterosexuals (64% vs 32%, respectively). 97 A UK survey of 395 MSM travelers in 1995 revealed that 48% reported at least one CSE while abroad. 124 The internationalization of STI risk in MSM was recently made very clear with the virtual simultaneous outbreaks of syphilis and lymphogranuloma venereum (LGV) in both Europe and the United States. 126

Condom Use

Limited and/or inconsistent condom use in travelers appears to be independent of country of origin, travel “style” (eg, business, back‐packer), and country of destination. 86,88,89,91,97,98,105,106,123,127–129 Overall, at least 33% to 50% of travelers do not consistently use condoms. Although many travelers carry condoms, they often “forget” to use them in the heat of the moment. 98,130 Even when condoms are used by travelers, there may be greater risks of failure due to poor quality of locally purchased products, 111 improper storage (ie, the bottom of the knapsack for 2 months at 40°C), improper application, or anal sex. 115,131,132

The Profile of the Traveler Who Will Have Sex Overseas

It should be obvious from the above that there is no single “profile” of the traveler likely to have CSE while traveling. 91,96 With few exceptions, questions related to anticipated or actual sexual activity are appropriate for almost every pretravel interview and every post‐travel review of systems. In this context, it is worth pointing out that the peak in new sexual partner acquisition in the teenage years is followed by a “second peak” among men and women 35 to 55 years of age (the “just‐divorced” group). 133 Finally, an ever‐greater number of elderly individuals are traveling to exotic locations, 134 and STIs among the elderly are easily overlooked. 135 Based upon their studies in Dutch travelers, de Graaf and colleagues divide travelers into four groups, with regard to CSE overseas: 92

  1. The “unprepared” (who are surprised when sex happens).

  2. The “fanatical” (who must have sex to have a successful vacation).

  3. The “unaffected” (who feel that sex abroad is the same as sex at home).

  4. The “slightly accessible” (who feel that sex abroad is different and come prepared).

Sexual Tourism

Although high levels of sexual activity have been documented in a wide range of travelers, “sexual tourism” is defined as travel expressly for the purpose of engaging in sexual activity. 5,136 Such travel is highly risky with respect to STIs, and prevention/harm reduction measures should be encouraged (eg, consistent condom use, reduction in the number of partners). In many instances, sexual tourism is exploitative and illegal (eg, seeking sex with a minor) and should be strongly discouraged (reviewed in Marrazzo 137 ). As noted above, the prevalence rates for STIs among CSW throughout the world can be very high (Table 3). However, relative risk gradients exist even in environments of overall elevated risk: street CSW generally have higher rates of STIs than their “higher class” competitors working in bars and hotels. 46,110 However, in 2006, there is probably no community in the world so isolated that its CSW can be considered to be even “relatively safe.” Risk mitigation strategies used by sexual tourists (eg, seeking virgins or ever‐younger CSW, insisting upon health certificates) are routinely thwarted. Some of these behaviors can also place travelers in serious jeopardy regarding both local and international laws.

Sexual Tourism by Another Name

The subtlety of sexual predation in the developing world must be explained to travelers. Many people in developing countries engage in sexual acts simply to survive: sex for a sandwich can be a fair trade in the eyes of a street child. 19,20,137 In many settings, the fact that a traveler is not paying money for sex does not mean that he/she is not buying sex. Effective “currencies” in many regions of the developing world include food, gifts, and even hope (ie, the chance to emigrate). The commercial nature of such transactions is often not appreciated or acknowledged by the Western traveler. Although legitimate “barmaids” and “pool boys” certainly exist in resort areas and lasting relationships are occasionally forged in such environments, both male and female travelers more often delude themselves or rationalize their behavior by falling “in love.” 130 As noted above, more female than male travelers follow through with their vacation trysts by longer term commitments such as assistance to emigrate. 95

Risk of Acquiring an STI During International Travel

The risk of acquiring one or more STIs while traveling depends entirely on the behavior of the traveler. There is no such thing as the “standardized sexual act.” As a result, accurate estimates for rates of STI transmission per exposure are very hard to generate. However, the following general rules apply to all situations:

  • Most STIs are more readily transmitted from males to females than the reverse.

  • Individuals with obvious lesions (eg, sores, ulcers, vesicles) are more likely to transmit the agents that caused the lesions as well as copathogens (eg, HIV, HBV) than individuals without any evident genital pathology.

  • Decisions about sexual partners and/or sex activities made under the influence of alcohol or drugs will increase the risk of acquiring STIs.

  • Sex acts that result in bleeding or that occur during menses significantly enhance the risk of transmitting and/or acquiring sexually transmitted, blood‐borne viruses (eg, HIV, hepatitis B and C viruses).

Because so many factors can influence risk, there have been relatively few attempts to quantify the risk of transmitting any given STI by individual sex acts. However, the risk of acquiring HIV, HBV, or HCV from a percutaneous injury are relatively well defined (0.5%, 4%–30%, and 3%–10%, respectively). 138 The risks following a single, unprotected, heterosexual, and consensual sex act are thought to be much lower: ∼.001% for HIV 139 and 0%–0.6% for HCV. 140 The presence of genital lesions can dramatically increase the risk of acquiring HIV and possibly other sexually transmitted viruses. A study of Kenyan men who acquired chancroid from HIV+ CSW suggested a 43% risk of HIV transmission following a single CSE. 141 The efficiency of purely sexual HBV transmission is currently unknown but is likely to be at least as high as HCV. 142 The transmission of gonorrhea and chlamydia is highly efficient during both hetero‐ and homosexual sex. A single episode of vaginal intercourse incurs a 20 and 50% risk of acquiring gonorrhea in uninfected men and women, respectively. 143 The transmission efficiencies for open syphilis and chancroid lesions are probably at least as high. Chlamydia trachomatis is transmitted heterosexually with only slightly lower efficiency (0.8%–8% per episode). 144 In a large study of Swiss travelers, Steffen estimated that hepatitis B, GC, and syphilis were acquired at rates of 4, 3, and ∼1 per 1,000 traveler months, respectively. 85 Reported rates of hepatitis B acquisition by unvaccinated, long‐term travelers have been as high as 4%–7% per year. 145,146

The Consequences of Acquiring an STI While Traveling

Acquisition of one or more STI can result in both short‐term problems (eg, genital ulcers, urethritis, cervicitis) and long‐term or chronic complications (eg, infertility and ectopic pregnancy, pelvic inflammatory disease, liver disease secondary to hepatitis B or C, cervical dysplasia secondary to human papillomavirus (HPV), immunodeficiency due to HIV). Several of these chronic infections can significantly shorten life [eg, cancer, liver cirrhosis, acquired immunodeficiency syndrome (AIDS)]. Both short‐ and long‐term consequences of acquiring any particular STI while traveling can vary substantially. Infections that manifest while traveling can expose travelers to products that are not used in the developed world (eg, chloramphenicol, serum‐based HBV vaccines) and to suboptimal medical practices and environments (eg, unsterilized needles/instruments). Some drugs and products such as hepatitis B immune globulin (HBIG) and antiretrovirals may not be readily available in some areas of the world or may be of unpredictable or unacceptably low potency. Infections that only manifest upon return of the traveler can also be problematic. Several of the STIs that can be acquired while traveling remain rare in North America and may go undiagnosed or be treated inappropriately by physicians who are unfamiliar with them (eg, chancroid, LGV). Finally, travelers who bring one or more STIs “home” to prior partners must also consider the emotional price including lost trust, broken relationships, and divorce.

Public Health Implications of STIs Acquired While Traveling

The potential impact of travel on STIs has significant public health implications in both departure and destination countries: the introduction of a new or more resistant organism can occur on either the outbound or the return voyage. Travelers who have CSEs overseas may also be more likely to engage in CSE back in their home country and vice versa. As a result, there are both small and large public health issues with CSE among travelers. At the “micro” level in the departure country, transmission of rare and/or resistant STIs to the nontraveling partner(s) must always be considered by treating physicians when confronted by a confusing clinical presentation. At the “macro” level, the potential to introduce exotic and/or resistant STIs into departure countries is very real. 7,62,63,147,148 Because so many people are currently traveling, the risk‐taking behavior of individuals can “add up” to epidemic spread rather quickly. For example, it has been estimated that >500,000 Australians have at least one CSE in the Philippines or Thailand every year. 75 Tourism and travel by truck and airline were major factors in the spread of HIV across Africa and then around the globe. 79 A recent survey among 1,325 male travelers in Hong Kong revealed that 453 (34.2%) had had at least one sexual contact with a CSW in the preceding 6‐month period. 149 The proportion of subjects presenting to some STI clinics with foreign sexual contact as their only risk factor can be impressive (10%–50%). 58,123,128,150 In 1993, Rowbottom estimated that at least 44% of GC cases in Victoria, Australia, had been acquired abroad. 75 Many of these imported STIs exhibit unusual or broad‐spectrum antibiotic resistance. 58

General Comments Regarding the Prevention and Treatment of STIs

The treatment of STIs has recently been reviewed in both the general population 151–153 and specifically in travelers. 33,78 Of course, the only way to reduce the risk of STIs to zero is abstinence or monogamous sex with a stable, uninfected partner. The following general statements apply to all STIs:

  • Condoms reduce the risk of most, but not all, STIs.

  • Prevention of STIs is preferred over treatment.

  • Partner notification is essential to prevent STI spread.

  • Prompt diagnosis and therapy can reduce both complications and spread.

  • Therapy should be guided by cultures and sensitivity tests when possible.

  • The presence of one STI should trigger a search for others.

  • Global resistance patterns should be considered when choosing antimicrobials.

Despite several new therapeutic strategies, 153 it is also worth pointing out that the treatment options for some of the most serious STIs remain very limited (eg, HBV, HCV). HIV can be controlled in most people for prolonged periods but at enormous financial and personal cost. For general treatment recommendations of the most common STIs, see Table 4. These recommendations have been abstracted largely from the Public Health Agency of Canada 151 and CDC guidelines. 152 The reader is encouraged to visit these sites to obtain more complete information.

Table 4

Overview of STI screening, diagnosis, and treatments

Clinical presentation and Regimen Appropriate investigations and follow‐up 
Asymptomatic but at risk (ie, CSE while traveling where STI status of contact(s) is not known) Culture or NAAT for Neisseria gonorrheae from all points of sexual contact (culture only for rectal and pharyngeal specimens) and/or urine for NAAT 
 NAAT or culture for Chlamydia trachomatis (urethral, cervical), culture for rectal and pharyngeal specimens (if the only point of sexual contact), and/or urine for NAAT 
 Serology for syphilis to include a nontreponemal test (eg, RPR, VDRL) or treponemal‐specific ELISA (or both) 
 Advise or consider HIV testing 
 HBV serology and offer HBV vaccination if not immune 
 Consider wet mount and/or culture for Trichimonas vaginalis 
 Consider HAV serology especially in the case of oral–anal contact and not vaccinated 
 Consider HCV serology especially in the case of IDU history 
Genital ulcer(s) (syphilis, HSV‐II, HSV‐I, chancroid, LGV, granuloma inguinale (donovanosis)) Darkfield microscopy or Immunofluorescence for Treponema pallidum (if available) 
 Serology for syphilis to include a nontreponemal test (eg, RPR, VDRL) or treponemal‐specific ELISA (or both) 
 GC culture or NAAT (where available) or antigen test for HSV 
 Consider serology for HSV (if lesions not present or suitable for above tests) 
 Culture or NAAT for C trachomatis (which if positive can be sent for DNA sequencing or RFLP to confirm LGV) 
 Culture or NAAT (where available) for Haemophilus ducreyi (alert laboratory, not widely available) 
 Advise or consider HIV testing 
Purulent urethritis/cervicitis (N gonorrheae, C trachomatis, rarely HSVI/II) Gram stain of discharge (looking for >5 WBCs per oil immersion field and GC) 
 Urethral or cervical swab: culture or NAAT for C trachomatis and N gonorrheae (latter requires special culture medium) 
 Consider urine specimen for NAAT 
Sexual assault Culture or NAAT for C trachomatis and N gonorrheae from all partially or fully penetrated orifices (culture only for rectal and pharyngeal specimens) 
 Cultures should be repeated 1 to 2 weeks postexposure in the absence of prophylaxis 
 Urine for NAAT for C trachomatis and N gonorrheae should also be collected 
 Wet mount and/or culture for T vaginalis 
 A nontreponemal (eg, RPR, VDRL) and a treponemal test (eg, TPPA) for syphilis (repeat at 12 and 24 weeks after exposure, and possibly at 2 to 4 weeks postassault if high risk) 
 If patient known to be immune to HBV, no testing is required; if not, serum sample for baseline antibodies to hepatitis B surface antigen 
 Baseline HIV antibody (repeat HIV serology at 6, 12, and 24 weeks) 
 Baseline HCV antibody is optional (consider HCV risk of perpetrator, and associated trauma during the assault—if performed should be repeated at 12 and 24 weeks) 
 Consider or advise PEP for bacterial STIs, HBV, and HIV (below) 
Choice of antimicrobial therapy for selected STIs (preferred regimens listed first, followed by alternates) 
Clinical presentation Regimen 
Chancroid (H ducreyiAzithromycin 1 g PO × 1 or ceftriaxone 250 mg IM × 1 or ciprofloxacin 500 mg PO BID × 3 days or erythromycin base 500 mg PO TID × 7 days 
Bacterial Vaginosis (Gardnerella vaginalisMetronidazole 500 mg BID × 7 days or metronidazole gel (0.75%) per vagina QD × 5 days or clindamycin cream (2%) per vagina QHS × 7 days 
Granuloma inguinale (Calymmatobacterium granulomatisDoxycycline 100 mg PO BID × 21 days (at least)* or trimethoprim‐sulfamethoxazole DS (800/160 mg) PO BID for 21 days (at least) or ciprofloxacin 750 mg PO BID for 21 days (at least) or erythromycin base 500 mg PO QID for 21 days (at least) or azithromycin 1 g PO once per week for 3 weeks (at least) 
HSV‐II (first episode) Acyclovir 400 mg PO TID × 7 to 10 days or acyclovir 200 mg PO five times/day × 7 to 10 days or famciclovir 250 mg PO TID × 7 to 10 days or valacyclovir 1 g PO BID × 7 to 10 days 
HSV‐II (recurrent) Acyclovir 400 mg PO TID × 5 days or acyclovir 200 mg PO five times/day × 5 days or acyclovir 800 mg PO BID × 5 days or famciclovir 125 mg PO BID × 5 days or valacyclovir 500 mg PO BID × 5 days or valacyclovir 1 g PO QD × 7 to 10 days 
Human papillomavirus Imiquimod cream (5%) applied to warts QHS 3 × per week for up to 16 weeks 
 Podofilox (0.5% solution or gel) applied QHS to warts × 3 days then 4 days “rest” for up to four cycles 
LGV (C trachomatis L1‐3) Doxycycline 100 mg PO BID × 21 days or erythromycin base 500 mg PO QID for 21 days or azithromycin 1g PO once per week for 21 days 
Neisseria gonorheae Cefixime 400 mg PO × 1 or ceftriaxone 125 mg IM × 1 or ciprofloxacin 500 mg PO × 1 or ofloxacin 400 mg PO BID × 7 days or levofloxacin 250 mg PO QD × 7 days or doxycycline 100 mg PO BID × 7 days or spectinomycin 2 g IM × 1 or gentamicin 240 mg IM × 1 or kanamycin 2 g IM × 1 
C trachomatis or Nongonococcal urethritis or Mucopurulent cervicitis Azithromycin 1 g PO × 1 or doxycycline 100 mg PO BID × 7 days or erythromycin base 500 mg PO QID × 7 days or erythromycin ethylsusuccinate 800 mg PO QID × 7 days or ofloxacin 300 mg PO BID × 7 days or levofloxacin 500 mg PO QD × 7 days 
Sexual assault Ceftriaxone 125 mg IM × 1 and metronidazole 2 g PO × 1 and azithromycin 1 g PO × 1 plus antiretrovirals (triple therapy such as Combivir + efavirenz), HBV vaccination (if unvaccinated) 
Syphilis (T pallidum) (primary) Benzathine penicillin G 2.4 million units IM × 1 or doxycycline 100 mg PO BID × 14 days or tetracycline 500 mg PO QID × 14 days or azithromycin 2 g PO × 1 (caution as efficacy may only be 70%) or ceftriaxone 1 g QD × 8 to 10 days 
T vaginalis Metronidazole 2 g PO × 1 
Clinical presentation and Regimen Appropriate investigations and follow‐up 
Asymptomatic but at risk (ie, CSE while traveling where STI status of contact(s) is not known) Culture or NAAT for Neisseria gonorrheae from all points of sexual contact (culture only for rectal and pharyngeal specimens) and/or urine for NAAT 
 NAAT or culture for Chlamydia trachomatis (urethral, cervical), culture for rectal and pharyngeal specimens (if the only point of sexual contact), and/or urine for NAAT 
 Serology for syphilis to include a nontreponemal test (eg, RPR, VDRL) or treponemal‐specific ELISA (or both) 
 Advise or consider HIV testing 
 HBV serology and offer HBV vaccination if not immune 
 Consider wet mount and/or culture for Trichimonas vaginalis 
 Consider HAV serology especially in the case of oral–anal contact and not vaccinated 
 Consider HCV serology especially in the case of IDU history 
Genital ulcer(s) (syphilis, HSV‐II, HSV‐I, chancroid, LGV, granuloma inguinale (donovanosis)) Darkfield microscopy or Immunofluorescence for Treponema pallidum (if available) 
 Serology for syphilis to include a nontreponemal test (eg, RPR, VDRL) or treponemal‐specific ELISA (or both) 
 GC culture or NAAT (where available) or antigen test for HSV 
 Consider serology for HSV (if lesions not present or suitable for above tests) 
 Culture or NAAT for C trachomatis (which if positive can be sent for DNA sequencing or RFLP to confirm LGV) 
 Culture or NAAT (where available) for Haemophilus ducreyi (alert laboratory, not widely available) 
 Advise or consider HIV testing 
Purulent urethritis/cervicitis (N gonorrheae, C trachomatis, rarely HSVI/II) Gram stain of discharge (looking for >5 WBCs per oil immersion field and GC) 
 Urethral or cervical swab: culture or NAAT for C trachomatis and N gonorrheae (latter requires special culture medium) 
 Consider urine specimen for NAAT 
Sexual assault Culture or NAAT for C trachomatis and N gonorrheae from all partially or fully penetrated orifices (culture only for rectal and pharyngeal specimens) 
 Cultures should be repeated 1 to 2 weeks postexposure in the absence of prophylaxis 
 Urine for NAAT for C trachomatis and N gonorrheae should also be collected 
 Wet mount and/or culture for T vaginalis 
 A nontreponemal (eg, RPR, VDRL) and a treponemal test (eg, TPPA) for syphilis (repeat at 12 and 24 weeks after exposure, and possibly at 2 to 4 weeks postassault if high risk) 
 If patient known to be immune to HBV, no testing is required; if not, serum sample for baseline antibodies to hepatitis B surface antigen 
 Baseline HIV antibody (repeat HIV serology at 6, 12, and 24 weeks) 
 Baseline HCV antibody is optional (consider HCV risk of perpetrator, and associated trauma during the assault—if performed should be repeated at 12 and 24 weeks) 
 Consider or advise PEP for bacterial STIs, HBV, and HIV (below) 
Choice of antimicrobial therapy for selected STIs (preferred regimens listed first, followed by alternates) 
Clinical presentation Regimen 
Chancroid (H ducreyiAzithromycin 1 g PO × 1 or ceftriaxone 250 mg IM × 1 or ciprofloxacin 500 mg PO BID × 3 days or erythromycin base 500 mg PO TID × 7 days 
Bacterial Vaginosis (Gardnerella vaginalisMetronidazole 500 mg BID × 7 days or metronidazole gel (0.75%) per vagina QD × 5 days or clindamycin cream (2%) per vagina QHS × 7 days 
Granuloma inguinale (Calymmatobacterium granulomatisDoxycycline 100 mg PO BID × 21 days (at least)* or trimethoprim‐sulfamethoxazole DS (800/160 mg) PO BID for 21 days (at least) or ciprofloxacin 750 mg PO BID for 21 days (at least) or erythromycin base 500 mg PO QID for 21 days (at least) or azithromycin 1 g PO once per week for 3 weeks (at least) 
HSV‐II (first episode) Acyclovir 400 mg PO TID × 7 to 10 days or acyclovir 200 mg PO five times/day × 7 to 10 days or famciclovir 250 mg PO TID × 7 to 10 days or valacyclovir 1 g PO BID × 7 to 10 days 
HSV‐II (recurrent) Acyclovir 400 mg PO TID × 5 days or acyclovir 200 mg PO five times/day × 5 days or acyclovir 800 mg PO BID × 5 days or famciclovir 125 mg PO BID × 5 days or valacyclovir 500 mg PO BID × 5 days or valacyclovir 1 g PO QD × 7 to 10 days 
Human papillomavirus Imiquimod cream (5%) applied to warts QHS 3 × per week for up to 16 weeks 
 Podofilox (0.5% solution or gel) applied QHS to warts × 3 days then 4 days “rest” for up to four cycles 
LGV (C trachomatis L1‐3) Doxycycline 100 mg PO BID × 21 days or erythromycin base 500 mg PO QID for 21 days or azithromycin 1g PO once per week for 21 days 
Neisseria gonorheae Cefixime 400 mg PO × 1 or ceftriaxone 125 mg IM × 1 or ciprofloxacin 500 mg PO × 1 or ofloxacin 400 mg PO BID × 7 days or levofloxacin 250 mg PO QD × 7 days or doxycycline 100 mg PO BID × 7 days or spectinomycin 2 g IM × 1 or gentamicin 240 mg IM × 1 or kanamycin 2 g IM × 1 
C trachomatis or Nongonococcal urethritis or Mucopurulent cervicitis Azithromycin 1 g PO × 1 or doxycycline 100 mg PO BID × 7 days or erythromycin base 500 mg PO QID × 7 days or erythromycin ethylsusuccinate 800 mg PO QID × 7 days or ofloxacin 300 mg PO BID × 7 days or levofloxacin 500 mg PO QD × 7 days 
Sexual assault Ceftriaxone 125 mg IM × 1 and metronidazole 2 g PO × 1 and azithromycin 1 g PO × 1 plus antiretrovirals (triple therapy such as Combivir + efavirenz), HBV vaccination (if unvaccinated) 
Syphilis (T pallidum) (primary) Benzathine penicillin G 2.4 million units IM × 1 or doxycycline 100 mg PO BID × 14 days or tetracycline 500 mg PO QID × 14 days or azithromycin 2 g PO × 1 (caution as efficacy may only be 70%) or ceftriaxone 1 g QD × 8 to 10 days 
T vaginalis Metronidazole 2 g PO × 1 

This table is designed as a quick reference and is not meant to replace more comprehensive guidelines (eg, Health Canada, 151 CDC 152 ). STI = sexually transmitted infections; NAAT = nucleic acid amplification test; IDU = intravenous drug use; RFLP = restriction fragment length polymorphism; PEP = postexposure prophylaxis; HIV = human immunodeficiency virus; LGV = lymphogranuloma venereum; GC = gonorrhea; HAV = hepatitis A virus; HBV = hepatitis B virus; HCV = hepatitis C virus; CSE = casual sex experience; TPPA =Treponema pallidum particle agglutination; WBC = white blood cell count; ELISA = enzyme‐linked immunosorbent assay; RPR = rapid plasmin reagin; VDRL = venereal diseases research laboratory.

*

Treat until lesions have healed completely. An aminoglycoside can be added to regimens above if no improvement seen in first week of therapy (eg, gentamicin 1mg/kg IV every 8 hours—monitor levels).

Prevention of STIs

Health care professionals who see international travelers should make advice about STIs and avoidance strategies a routine part of the pretravel visit. Among the microbial risks of travel, the STIs are probably second only to malaria in terms of their potential for serious morbidity and mortality. Safer sex and harm reduction counseling should be emphasized. Barrier contraceptive devices, specifically male and female condoms, provide the best alternative to abstinence by preventing direct contact with infective genital lesions. Although male and female condoms are likely to have similar efficacy for many STIs when used appropriately, almost all of the available data come from studies of male condom use. Condoms made from latex provide a more effective barrier than “natural” condoms made from animal membranes. In experimental models, the latter are not impervious to viruses such as hepatitis B, hepatitis C, and HIV. 152 In the event that a latex condom is not available, natural condoms do provide some degree of protection against a range of pathogens and are certainly better than nothing. If possible, latex condoms should be purchased in a developed world country since the quality of condoms produced in many regions of the world is inconsistent. 111 Only water‐base lubricants should be used with condoms since oil‐based products (eg, petroleum jelly, mineral oil, massage oil) can significantly weaken latex condoms and lead to breakage. 152 High‐quality polyurethane condoms are available in most developed world countries for travelers with latex allergies. 154

The reported efficacy of latex condoms against STIs ranges from 40% to 70%, 155 but the contraceptive literature suggests that consistent and correct use can reduce the risk of heterosexual HIV transmission by 80%. They are generally more effective against viral pathogens spread by semen, vaginal secretions, and blood than bacterial agents associated with lesions around the genitalia. The most serious limitation of condoms is their inability to spontaneously migrate from pocket to penis (see above). The most common factors involved in condom breakage include inappropriate application, repeated or prolonged use, and anal intercourse. Although not as widely available as standard male condoms, the so‐called female condom can also be a relatively effective barrier against STIs. 156,157 Spermicides, such as nonoxynol‐9, interfere with sperm viability, and early studies suggested a protective effect against a range of sexually transmitted viruses and bacteria. 158 However, a recent Cochrane Database review suggests that nonoxynol‐9 has no protective effect against a range of pathogens. 159,160 In fact, with too frequent vaginal use or use in anal receptive intercourse, nonoxynol‐9 can disrupt epithelial integrity and lead to increased transmission of HIV and other STIs. 159,160

Screening for STIs is appropriate for many travelers who report CSE while abroad. 161,162 Such screening should be guided by the nature of the sexual contact and current or past symptoms and could include an examination of the genitals, a cervical/urethral/anal/pharyngeal swab and/or urine testing as well as serologic tests for syphilis, HIV, and possibly HBV and HCV (Table 4).

The “Morning‐After” STI Pill

Although it may be tempting to “arm” travelers likely to engage in high‐risk sexual activities while abroad (eg, by stated intention or past behavior) with a morning‐after course of antibiotic therapy, this practice is not recommended. Ready access to antibiotics could lead to a false sense of security and increased exposure to STIs not targeted by the therapy provided (eg, HIV, HCV, HPV). Such behavioral effects have recently been documented among CSW. 163

Postexposure Prophylaxis for Sexual Assault Victims

The management of sexual assault victims has recently been reviewed. 164–166 Women traveling for prolonged periods of time in developing world countries should be counseled with regards to risk mitigation strategies in the event of sexual assault. In all such long‐term travelers (male and female), verification of hepatitis B vaccination status should be routine. Unvaccinated travelers who have been assaulted should begin active immunization as well as HBIG if a trustworthy product can be found locally. Individuals with incomplete immunization schedules must be reviewed on a case‐by‐case basis (ie, complete or reinitiate active immunization with or without HBIG). Although postexposure prophylaxis (PEP) for HIV using three drugs would be appropriate in many circumstances, these combinations are expensive (eg, ∼US$1,500 for 28 days of 3TC+AZT plus efavirenz) and would not be appropriate to prescribe for all travelers. However, such an expenditure might be reasonable for groups living or working overseas for prolonged periods (eg, semester abroad, large international projects). Many institutions in the developing world (eg, embassies, private schools, industries) have access to appropriate HIV PEP drugs. An alternate and lower cost strategy for individual travelers might be the purchase of a “starter kit” with 3 to 5 days of PEP drugs (US$160–$260). In some countries with high rates of sexual assault and limited availability of antiretrovirals (eg, South Africa), specific insurance policies can be purchased to ensure access to HIV PEP. It is logical to offer broad prophylaxis for other STIs if it is unsure whether or not the victim of assault will return, if the assailant has a known STI, if prophylaxis is requested or if the assault victim has signs and symptoms of an STI (see Table 4). However, the efficacy of prophylaxis following sexual assault has not been studied. Unintended pregnancy may also result from sexual assault, and the emergency contraceptive pill may also be considered in these circumstances. Treatment should be taken as soon as possible (0–72 hours for maximum efficacy) but may be of benefit up to 120 hours after exposure. 167

Special Traveling Groups

Pregnant and Lactating Women

Pregnancy is also one of the major risks of CSE in any setting. Although few data are available, pregnancy does not appear to be a major risk factor for the acquisition or evolution of most STIs, although treatment can be complicated by the presence of the fetus.

Children

As a general rule, most children who travel do so with their parents and are relatively unlikely to be at high risk for the sexually transmitted disease. However, it is worth noting that developing world children are common targets of the sex trade. Tens, if not hundreds or thousands, of street children work in the sex trade in many cities of the developing world. 19,20,137

Adolescents and Young Adults

Adolescents and young adults are at particularly high risk for acquiring and spreading STIs. Peak acquisition of new sexual partners occurs in all cultures during the teen and early adult years. 133

Immunocompromised Hosts

A recent survey of 133 HIV+ Canadian travelers (93% male) suggest these individuals are as likely as their noninfected peers to engage in casual sex while overseas (23%) and are just as unlikely to use condoms consistently (only 58%). 125 Not only do STIs facilitate the transmission of HIV but also the diagnosis of these infections, their clinical presentation, and treatment can all be influenced by HIV (reviewed by Dallabetta 166 ). HIV+ subjects are more likely to have asymptomatic primary syphilis and to progress rapidly to neurologic and ophthalmologic complications. 168 GC is more severe and more likely to disseminate in HIV+ subjects. 166 Pelvic inflammatory disease of all etiologies is more common and severe, 169,170 and molluscum contagiosum can be profuse in HIV/AIDS patients. 171 With the exception of neurosyphilis that can be difficult to treat, STIs in HIV+ subjects can generally be expected to respond to standard therapy. 150,151,166,171 It is worth noting that HIV testing is increasingly demanded of immigrants and refugees in many countries. 172,173 There has been a parallel worldwide increase in mandatory HIV testing for long‐term, nonresident visas (eg, expatriates, students, missionaries).

The Mature or Elderly Traveler

Sexual activity with all its attendant pleasures and risks, is a central part of a healthy life at all ages. 134,135,174 As noted above, the rapid acquisition of new sexual partners is not restricted to the teenage years: a second peak between the ages of 45 to 55 has been described even among nontravelers (the restless and the divorced). 133 It is important not to make assumptions about the actual or intended sexual activity of either male or female travelers at any age.

Barriers to the Promotion of Sexual Health in Travelers

Several obstacles to the promotion of sexual health in travelers have recently been discussed by Abdullah and colleagues 8 These include traveler diversity, the ambivalence of both the travel industry and destination governments to a frank discussion of the risks of sexual encounters while abroad and a lack of support for travel counseling and preventative services in many departure countries. As noted above, there is often a pervasive and even willful denial of both sexual risk and responsibility among developed world travelers. In this context, a forced discussion of sexual behaviors and responsibility can be intrusive and unwanted. Furthermore, as pointed out by Sanford, 175 the role of the travel advisor is not to be a killjoy but to help each traveler find a reasonable balance between risk acceptance and appropriate risk avoidance or mitigation.

Advocacy for Sexual Health in Travelers

The rapidity with which international travel has expanded in recent years has provided unprecedented potential for the development of global sexual networks. Holiday, business, and VFR travelers each present particular challenges to travel medicine practitioners. At the current time, travel health messages reach only a tiny proportion of the traveling community (certainly <20%). 176 Innovative approaches are needed to gain access to these diverse groups of travelers and to encourage the travel industry and both departure and destination governments to accept responsibility for ensuring that sexual health issues receive the attention that they deserve.

Conclusions

Individuals who acquire new sexual partners while traveling, especially those who pay for sex or have multiple CSEs overseas, are at risk for a wide range of STIs. Although the behaviors of some travelers put them at higher risk of contracting STIs, there is no single profile of the “at‐risk” traveler. Barrier contraceptives can provide some degree of protection against many STIs, but 100% protection cannot be achieved even with meticulous use. Only HBV and HPV genotypes can currently be prevented by vaccination, although vaccines for chlamydia species and HSV‐II (among others) are in development. 177 Although drug resistance is more commonly encountered in STIs acquired overseas, all the bacterial STIs can be treated successfully at the current time if appropriate antimicrobials are chosen. A series of evidence‐based recommendations for managing travelers and STIs are presented in Table 5. 178

Table 5

Evidence‐based* recommendations for managing travelers and STIs

Evidence‐based recommendations related to behaviors 
Evidence‐based recommendations related to behaviors 
 Alcohol and drugs contribute to unhealthy decisions regarding sex and condom use (AII) 
 Solo travel and same‐sex groups increase the risk of CSEs (AII) 
 Male travelers are more likely to have CSE and to buy sex than females (AII) 
 Sexual contact with a CSW is always a high‐risk behavior (AII) 
 Men and women with multiple sexual partners at home or a history of STIs are more likely to have CSE while traveling (AII) 
 Sexual tourism is highly risky with respect to STIs (EIII) 
 Sexual tourism with minors is illegal (EIII) 
Evidence‐based recommendations related to prophylaxis 
 A discussion of STI risk and prevention should be part of pretravel counseling (AII) 
 Hepatitis B vaccination should be offered to all travelers who may have CSE (AI) 
 Hepatitis A vaccination should be offered to those who anticipate oral–anal contact (AI) 
 Condoms reduce the risk of most, but not all, STIs (AII) 
 Spermicides should not be used without a condom (AII) 
 Condoms should be used for all casual sexual encounters (male AI, female AII) 
 Use condoms manufactured in the developed world and stored appropriately (AI) 
 Natural condoms do not protect against viral STIs and should not be used if reliable latex or polyurethane condoms  are available (DI) 
 Reuse of condoms and use for anal intercourse will increase the risk of breakage (AII) 
 Oil‐based lubricants should not be used with latex condoms (EI) 
Evidence‐based recommendations related to treatment and screening 
 Travelers who have had CSEs overseas should be assessed for STIs by a reliable clinic abroad or upon their return to  Canada (AIII) 
 Obtain sensitivity testing for all bacterial STIs acquired while traveling (AIII) 
 Follow national/international guidelines for the empiric treatment of STIs while waiting for culture results (AI) 
 Consider all the possible STIs to which a traveler may have been exposed during CSEs and screen appropriately (AIII) 
Evidence‐based recommendations related to behaviors 
Evidence‐based recommendations related to behaviors 
 Alcohol and drugs contribute to unhealthy decisions regarding sex and condom use (AII) 
 Solo travel and same‐sex groups increase the risk of CSEs (AII) 
 Male travelers are more likely to have CSE and to buy sex than females (AII) 
 Sexual contact with a CSW is always a high‐risk behavior (AII) 
 Men and women with multiple sexual partners at home or a history of STIs are more likely to have CSE while traveling (AII) 
 Sexual tourism is highly risky with respect to STIs (EIII) 
 Sexual tourism with minors is illegal (EIII) 
Evidence‐based recommendations related to prophylaxis 
 A discussion of STI risk and prevention should be part of pretravel counseling (AII) 
 Hepatitis B vaccination should be offered to all travelers who may have CSE (AI) 
 Hepatitis A vaccination should be offered to those who anticipate oral–anal contact (AI) 
 Condoms reduce the risk of most, but not all, STIs (AII) 
 Spermicides should not be used without a condom (AII) 
 Condoms should be used for all casual sexual encounters (male AI, female AII) 
 Use condoms manufactured in the developed world and stored appropriately (AI) 
 Natural condoms do not protect against viral STIs and should not be used if reliable latex or polyurethane condoms  are available (DI) 
 Reuse of condoms and use for anal intercourse will increase the risk of breakage (AII) 
 Oil‐based lubricants should not be used with latex condoms (EI) 
Evidence‐based recommendations related to treatment and screening 
 Travelers who have had CSEs overseas should be assessed for STIs by a reliable clinic abroad or upon their return to  Canada (AIII) 
 Obtain sensitivity testing for all bacterial STIs acquired while traveling (AIII) 
 Follow national/international guidelines for the empiric treatment of STIs while waiting for culture results (AI) 
 Consider all the possible STIs to which a traveler may have been exposed during CSEs and screen appropriately (AIII) 

CSW = commercial sex workers; STI = sexually transmitted infections; CSE = casual sex experience.

*

Strength of Recommendation scored as A Good evidence to support a recommendation for use. B Moderate evidence to support a recommendation for use. C Poor evidence to support a recommendation for or against use. D Moderate evidence to support a recommendation against use. E Good evidence to support a recommendation against use.Quality of Evidence scored as   I Evidence from at least one properly randomized, controlled trial.  II Evidence from at least one well‐designed clinical trial without randomization, from cohort or case‐controlled analytic studies, preferably from more than one centre, from multiple time series, or dramatic results in uncontrolled experiments. III Evidence from opinions of respected authorities on the basis of clinical experience, descriptive studies, or reports of expert committees.178

Declaration of Interests

The authors state that they have no conflicts of interest.

References

1
Zimmerman
C
.
Violence against women: global scope and magnitude
.
Lancet
 
2002
;
359
:
1232
1237
.
2
Rogers
S
.
Rolling down to old Maui
. Available at: http://www.ifred.ca/stanrogers/songs.html. (Accessed 2006 Aug 16)
3
Watt
J
.
Lettsomian lectures. Medical perspectives of some voyages of discovery
.
Trans Roy Soc Lond
 
1979
;
95
:
61
91
.
4
World Tourism Organization
.
Tourism highlight 2003
. Available at: http://www.world-tourism.org/market_research/facts/menu.html. (Accessed 2006 Aug 21)
5
Mulhall
BP
.
Sex and travel: studies of sexual behaviour, disease and health promotion in international travelers—a global review
.
Int J STD AIDS
 
1996
;
7
:
455
465
.
6
Aral
SO
.
Sexually transmitted diseases: magnitude, determinants and consequences
.
Int J STD AIDS
 
2001
;
12
:
211
215
.
7
Aral
SO
.
Determinants of STI epidemics: implications for phase appropriate intervention strategies
.
Sex Transm Infect
 
2002
;
78
(
Suppl 1
):
3
13
.
8
Abdullah
AS
Ebrahim
SH
Fielding
R
Morisky
DE
.
Sexually transmitted infections in travelers: implications for prevention and control
.
Clin Infect Dis
 
2004
;
39
:
533
538
.
9
World Health Organization
.
Global prevalence and incidence of selected curable sexually transmitted infections: overview and estimates
.
Geneva
: WHO. WHO/CDS/CSR/EDC/2001.10. 2001;
1
54
.
10
Ruiz
J
.
Street youth in Colombia: lifestyle, attitudes and knowledge
.
AIDS Health Promot Exch
 
1994
;
1
:
12
14
.
11
Msuya
W
Mayaud
P
Mkanje
R
Grosskurth
H
.
Taking early action in emergencies to reduce the spread of STIs and HIV
.
Afr Health
 
1996
;
18
:
24
.
12
Van Den Hoek
A
.
STI control in drug users and street youth
.
Genitourin Med
 
1997
;
73
:
240
244
.
13
Rew
L
.
Sexual health practices of homeless youth: a model for intervention
.
Issues Compr Pediatr Nurs
 
2001
;
24
:
1
18
.
14
Roy
E
Haley
N
Leclerc
P
, et al.
Mortality in a cohort of street youth in Montreal
.
JAMA
 
2004
;
292
:
569
574
.
15
World Health Organization
.
WHO. Office of Information. Sexually transmitted infections ncreasing—250 million new infections annually
.
WHO Feature
 
1990
;
152
:
1
6
.
16
Gerbase
AC
Rowley
JT
Heymann
DH
, et al.
Global prevalence and incidence estimates of selected curable STIs
.
Sex Transm Infect
 
1998
;
74
(
Suppl 1
):
S12
S16
.
17
Gerbase
AC
Rowley
JT
Mertens
TE
.
Global epidemiology of sexually transmitted diseases
.
Lancet
 
1998
;
351
:
2
4
.
18
Shetty
AK
Powell
G
.
Children orphaned by AIDS: a global perspective
.
Semin Pediatr Infect Dis
 
2003
;
14
:
25
31
.
19
Foster
G
.
Africa’s children and AIDS‐a continent in crisis
. The devastators of the HIV/AIDS pandemic. AIDS link 1997 May‐June; 4–5.
20
Anonymous.
Street children turn to sex‐work to survive
.
AIDS Anal Afr
 
1995
;
5
:
6
7
.
21
Brunham
RC
Plummer
FA
.
A general model of sexually transmitted disease epidemiology and its implications for control
.
Med Clin North Am
 
1990
;
74
:
1339
1352
.
22
Saphonn
V
Hor
LB
Ly
SP
, et al.
How well do antenatal clinic (ANC) attendees represent the general population? A comparison of HIV prevalence from ANC sentinel surveillance sites with a population‐based survey of women aged 15‐49 in Cambodia
.
Int J Epidemiol
 
2002
;
31
:
449
455
.
23
Aboyeji
AP
Nwabuisi
C
.
Prevalence of sexually transmitted diseases among pregnant women in Ilorin, Nigeria
.
J Obstet Gynaecol
 
2003
;
23
:
637
639
.
24
Latif
AS
Bvumbe
J
Muongerwa
J
, et al.
Sexually transmitted diseases in pregnant women in Harare, Zimbabwe
.
Afr J Sex Transmi Dis
 
1984
;
1
:
21
23
.
25
Duncan
ME
Tibaux
G
Kloos
H
, et al.
STIS in women attending family planning clinics: a case study in Addis Ababa
.
Soc Sci Med
 
1997
;
44
:
441
454
.
26
Pham‐Kanter
GB
Steinberg
MH
Ballard
RC
.
Sexually transmitted diseases in South Africa
.
Genitourin Med
 
1996
;
72
:
160
171
.
27
Blankhart
D
Muller
O
Gresenguet
G
Weis
P
.
Sexually transmitted infections in young pregnant women in Bangui, Central African Republic
.
Int J STD AIDS
 
1999
;
10
:
609
614
.
28
Kilmarx
PH
Black
CM
Limpakarnjanarat
K
, et al.
Rapid assessment of sexually transmitted diseases in a sentinel population in Thailand: prevalence of chlamydial infection, gonorrhoea, and syphilis among pregnant women—1996
.
Transm Infect
 
1998
;
74
:
189
193
.
29
Thomas
K
Thyagarajan
SP
Jeyaseelan
L
, et al.
Community prevalence of sexually transmitted diseases and human immunodeficiency virus infection in Tamil Nadu, India: a probability proportional to size cluster survey
.
Natl Med J India
 
2002
;
15
:
135
140
.
30
Purevdawa
E
Moon
TD
Baigalmaa
C
, et al.
Rise in sexually transmitted diseases during democratization and economic crisis in Mongolia
.
Int J STD AIDS
 
1997
;
8
:
398
401
.
31
Cowan
FM
French
RS
Mayaud
P
, et al.
Seroepidemiological study of herpes simplex virus types 1 and 2 in Brazil, Estonia, India, Morocco, and Sri Lanka
.
Sex Transm Infect
 
2003
;
79
:
286
290
.
32
Parenti
DM
.
Sexually transmissible diseases and travelers
.
Med Clin North Am
 
1992
;
76
:
1449
1461
.
33
Wang
CC
Celum
CL
.
Global risk of sexually transmitted diseases
.
Med Clin North Am
 
1999
;
83
:
975
995
.
34
Ndoye
I
Mboup
S
De Schryver
A
, et al.
Diagnosis of sexually transmitted infections in female prostitutes in Dakar, Senegal
.
Sex Transm Infect
 
1998
;
74
(
Suppl 1
):
S112
S117
.
35
Ramjee
G
Karim
SS
Sturm
AW
.
Sexually transmitted infections among sex workers in KwaZulu‐Natal, South Africa
.
Sex Transm Dis
 
1998
;
25
:
346
349
.
36
Van Den Hoek
A
Yuliang
F
Dukers
NH
, et al.
High prevalence of syphilis and other sexually transmitted diseases among sex workers in China: potential for fast spread of HIV
.
AIDS
 
2001
;
15
:
753
759
.
37
Sugihantono
A
Slidell
M
Syaifudin
A
, et al.
Syphilis and HIV prevalence among commercial sex workers in Central Java, Indonesia: risk‐taking behavior and attitudes that may potentiate a wider epidemic
.
AIDS Patient Care STDS
 
2003
;
17
:
595
600
.
38
Ford
K
Wirawan
DN
Reed
BD
, et al.
AIDS and STI knowledge, condom use and HIV/STI infection among female sex workers in Bali, Indonesia
.
AIDS Care
 
2000
;
12
:
523
534
.
39
Joesoef
MR
Linnan
M
Barakbah
Y
, et al.
Patterns of sexually transmitted diseases in female sex workers in Surabaya, Indonesia
.
Int J STD AIDS
 
1997
;
8
:
576
580
.
40
Sarkar
S
Islam
N
Durandin
F
, et al.
Low HIV and high STI among commercial sex workers in a brothel in Bangladesh: scope for prevention of larger epidemic
.
Int J STD AIDS
 
1998
;
9
:
45
47
.
41
Joesoef
MR
Gultom
M
Irana
ID
, et al.
High rates of sexually transmitted diseases among male transvestites in Jakarta, Indonesia
.
Int J STD AIDS
 
2003
;
14
:
609
613
.
42
Camejo
MI
Mata
G
Diaz
M
.
Prevalence of hepatitis B, hepatitis C and syphilis in female sex workers in Venezuela
.
Rev Saude Publica
 
2003
;
37
:
339
344
.
43
Mesquita
PE
Granato
CF
Castelo
A
.
Risk factors associated with hepatitis C virus (HCV) infection among prostitutes and their clients in the city of Santos, Sao Paulo State, Brazil
.
J Med Virol
 
1997
;
51
:
338
343
.
44
Hyams
KC
Phillips
IA
Tejada
A
, et al.
Three‐year incidence study of retroviral and viral hepatitis transmission in a Peruvian prostitute population
.
J Acquir Immune Defic Syndr
 
1993
;
6
:
1353
1357
.
45
Russi
JC
Serra
M
Vinoles
J
, et al.
Sexual transmission of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus type 1 infections among male transvestite comercial sex workers in Montevideo, Uruguay
.
Am J Trop Med Hyg
 
2003
;
68
:
716
720
.
46
Laurent
C
Henzel
D
Mulanga‐Kabeya
C
, et al.
Seroepidemiological survey of hepatitis C virus among commercial sex workers and pregnant women in Kinshasa, Democratic Republic of Congo
.
Int J Epidemiol
 
2001
;
30
:
872
877
.
47
Pando
MA
Berini
C
Bibini
M
, et al.
Prevalence of HIV and other sexually‐transmitted infections among female commercial sex workers in Argentina
.
Am J Trop Med Hyg
 
2006
;
74
:
233
238
.
48
Lavanchy
D
.
Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures
.
J Viral Hepat
 
2004
;
11
:
97
107
.
49
Ray Kim
W
.
Global epidemiology and burden of hepatitis C
.
Microbes Infect
 
2002
;
4
:
1219
1225
.
50
The Global Burden of Hepatitis C Working Group
.
Global burden of disease (GBD) for hepatitis C
.
J Clin Pharmacol
 
2004
;
44
:
20
29
.
51
Edlich
RF
Arnette
JA
Williams
FM
.
Global epidemic of human T‐cell lymphotropic virus type‐I (HTLV‐I)
.
J Emerg Med
 
2000
;
18
:
109
119
.
52
Erbelding
E
Quinn
TC
.
The impact of antimicrobial resistance on the treatment of sexually transmitted diseases
.
Infect Dis Clin North Am
 
1997
;
11
:
889
903
.
53
CDC
.
Global distribution of penicillinase‐producing Neisseria gonorrhoeae (PPNG)
.
MMWR Morb Mortal Wkly Rep
 
1982
;
31
:
1
3
.
54
Brown
S
Warnnissorn
T
Biddle
J
, et al.
Antimicrobial resistance of Neisseria gonorrhoea in Bangkok: is single‐drug treatment passe
.
Lancet
 
1982
;
2
:
1366
1368
.
55
Bodonaik
NC
.
Decrease in the incidence of tetracycline resistance in strains of Neisseria gonorrhoeae in the nineties
.
West Indian Med J
 
2003
;
52
:
228
230
.
56
Bogaerts
J
Van Dyck
E
Mukantabana
B
, et al.
Auxotypes, serovars, and trends of antimicrobial resistance of Neisseria gonorrhoeae in Kigali, Rwanda (1985‐93)
.
Sex Transm Infect
 
1998
;
74
:
205
209
.
57
Ison
CA
Dillon
JA
Tapsall
JW
.
The epidemiology of global antibiotic resistance among Neisseria gonorrhoeae and Haemophilus ducreyi
.
Lancet
 
1998
;
351
(
Suppl 3
):
8
11
.
58
De Schryver
A
Meheus
A
.
International travel and sexually transmitted diseases
.
World Health Stat Q
 
1989
;
42
:
90
99
.
59
De Schryver
A
Meheus
A
.
Epidemiology of sexually transmitted diseases: the global picture
.
Bull World Health Organ
 
1990
;
68
:
639
654
.
60
Yeung
KH
Dillon
JA
.
Cases of Neisseria gonorrhoeae with plasmid‐mediated resistance to penicillin increase. The National Study Group
.
Can Dis Wkly Rep
 
1990
;
16
:
13
16
.
61
Ng
LK
Martin
I
Lau
A
;
The National Gonococcal Surveillance Program Members. Trends of chromosomally mediated antimicrobial resistance in Neisseria gonorrhoeae in Canada: 1994‐1999
.
Sex Transm Dis
 
2003
;
30
:
896
900
.
62
Sarwal
S
Wong
T
Sevigny
C
Ng
LK
.
Increasing incidence of ciprofloxacin‐resistant Neisseria gonorrhoeae infection in Canada
.
CMAJ
 
2003
;
168
:
872
873
.
63
Patrick
D
Shaw
C
Rekart
ML
.
Neisseria gonorrhoeae with decreased susceptibility to ciprofloxacin in British Columbia: an imported phenomenon
.
Can Commun Dis Rep
 
1995
;
21
:
137
139
.
64
Ehret
JM
Judson
FN
.
Quinolone‐resistant Neisseria gonorrhoeae: the beginning of the end? Report of quinolone‐resistant isolates and surveillance in the southwestern United States, 1989 to 1997
.
Sex Transm Dis
 
1998
;
25
:
522
526
.
65
Herida
M
Sednaoui
P
Goulet
V
.
Gonorrhoea surveillance system in France: 1986‐2000
.
Sex Transm Dis
 
2004
;
31
:
209
214
.
66
Carballo
M
Pauze
M
Dillon
JR
.
Increase of Neisseria gonorrhoeae isolates with combined plasmid-mediated resistance to tetracycline (TRNG) and penicillin (PPNG)
 . Can Dis Wkly Rep
1990
;
16
:
219
222
.
67
Rousseau
D
Nadeau
D
Lafontaine
G
.
Emergence of spectinomycin‐resistant strains of penicillinase‐producing Neisseria gonorrhoeae (PPNG)—Quebec
.
Can Dis Wkly Rep
 
1989
;
15
:
101
102
; discussion 102–103.
68
Ray
K
Bala
M
Kumari
S
Narain
JP
.
Antimicrobial resistance of Neisseria gonorrhoeae in selected World Health Organization Southeast Asia Region countries: an overview
.
Sex Transm Dis
 
2005
;
32
:
178
184
.
69
Mann
J
Kropp
R
Wong
T
Venne
S
Romanowski
B
.
Gonorrhea treatment guidelines in Canada: 2004 update
.
CMAJ
 
2004
;
171
:
1345
1346
.
70
Rutanarugsa
A
Vorachit
M
Polnikorn
N
Jayanetra
P
.
Drug resistance of Haemophilus ducreyi
.
Southeast Asian J Trop Med Public Health
 
1990
;
21
:
185
193
.
71
Harries
AD
Nyangulu
DS
Hargreaves
NJ
, et al.
Preventing antiretroviral anarchy in sub‐Saharan Africa
.
Lancet
 
2001
;
358
:
410
414
.
72
Blower
S
Ma
L
Farmer
P
Koenig
S
.
Predicting the impact of antiretrovirals in resource‐poor settings: preventing HIV infections whilst controlling drug resistance
.
Curr Drug Targets Infect Disord
 
2003
;
3
:
345
353
.
73
Nkengasong
JN
Adje‐Toure
C
Weidle
PJ
.
HIV antiretroviral drug resistance in Africa
.
AIDS Rev
 
2004
;
6
:
4
12
.
74
Steffen
R
DeBernardis
C
Banos
A
.
Travel epidemiology—a global perspective
.
Int J Antimicrob Agents
 
2003
;
21
:
89
95
.
75
Rowbottom
J
.
STIs and the overseas traveller
.
Aust Fam Physician
 
1993
;
22
:
125
131
.
76
Mulhall
BP
Hu
M
Thompson
M
, et al.
Planned sexual behaviour of young Australian visitors to Thailand
.
Med J Aust
 
1993
;
158
:
530
535
.
77
Bloor
M
Thomas
M
Hood
K
, et al.
Differences in sexual risk behaviour between young men and women travelling abroad from the UK
.
Lancet
 
1998
;
352
:
1664
1668
.
78
Hawkes
S
Hart
G
.
The sexual health of travelers
.
Infect Dis Clin North Am
 
1998
;
12
:
413
430
.
79
Forsythe
S
.
HIV/AIDS and tourism
.
AIDS Anal Afr
 
1999
;
9
:
4
6
.
80
Fenton
KA
Chinouya
M
Davidson
O
Copas
A
,
MAYISHA research team. HIV transmission risk among sub‐Saharan Africans in London travelling to their countries of origin
.
AIDS
 
2001
;
15
:
1442
1445
.
81
Matteelli
A
Carosi
G
.
Sexually transmitted diseases in travelers
.
Clin Infect Dis
 
2001
;
32
:
1063
1067
.
82
Correia
JD
Shafer
RT
Patel
V
, et al.
Blood and body fluid exposure as a health risk for international travelers
.
J Travel Med
 
2001
;
8
:
263
266
.
83
Bellis
MA
Hughes
K
Thomson
R
Bennett
A
.
Sexual behaviour of young people in international tourist resorts
.
Sex Transm Infect
 
2004
;
80
:
43
47
.
84
Hynes
NA
.
Sexually transmitted diseases in travelers
.
Curr Infect Dis Rep
 
2005
;
7
:
132
137
.
85
Steffen
R
Rickenbach
M
Wilhelm
U
, et al.
Health problems after travel to developing countries
.
J Infect Dis
 
1987
;
156
:
84
91
.
86
Finney
H
.
Contraceptive use by medical students whilst on holiday
.
Fam Pract
 
2003
;
20
:
93
.
87
Arvidson
M
Hellberg
D
Mardh
PA
.
Sexual risk behavior and history of sexually transmitted diseases in relation to casual travel sex during different types of journeys
.
Acta Obstet Gynecol Scand
 
1996
;
75
:
490
494
.
88
Cabada
MM
Echevarria
JI
Seas
CR
, et al.
Sexual behavior of international travelers visiting Peru
.
Sex Transm Dis
 
2002
;
29
:
510
513
.
89
Cabada
MM
Montoya
M
Echevarria
JI
, et al.
Sexual behavior in travelers visiting Cuzco
.
J Travel Med
 
2003
;
10
:
214
218
.
90
Batalla‐Duran
E
Oakeshott
P
Hay
P
.
Sun, sea and sex? Sexual behaviour of people on holiday in Tenerife
.
Fam Pract
 
2003
;
20
:
493
494
.
91
Gagneux
OP
Blochliger
CU
Tanner
M
Hatz
CF
.
Malaria and casual sex: what travelers know and how they behave
.
J Travel Med
 
1996
;
3
:
14
21
.
92
De Graaf
R
Van Zessen
G
Houweling
H
.
Underlying reasons for sexual conduct and condom use among expatriates posted in AIDS endemic areas
.
AIDS Care
 
1998
;
10
:
651
665
.
93
Bonneaux
L
Van der Stuyft
P
Taelman
H
, et al.
Risk factors for infection with human immunodeficiency virus among European expatriates in Africa
.
BMJ
 
1988
;
297
:
581
584
.
94
Jones
ME
.
HIV and the returning expatriate
.
J Travel Med
 
1999
;
6
:
99
106
.
95
Herold
ES
Van Kerkwijk
C
.
AIDS and sex tourism
.
AIDS Soc
 
1992
;
4
:
1
,
8
.
96
Stricker
M
Steffen
R
Hornung
R
, et al.
Flûchtige sexuelle Kontakte von Scheizer Touristen in den Tropen
.
Mûnch Med Wschr
 
1990
;
132
:
175
177
.
97
Tveit
KS
Nilsen
A
Nyfors
A
.
Casual sexual experience abroad in patients attending an STI clinic and at high risk for HIV infection
.
Genitourin Med
 
1994
;
70
:
12
14
.
98
Gillies
P
Slack
R
Stoddart
N
Conway
S
.
HIV‐related risk behaviour in UK holiday‐makers
.
AIDS
 
1992
;
6
:
339
341
.
99
Bryant
KJ
.
Decreasing HIV/STI risk in relation to alcohol use: a research agenda
.
AIDS STD Health Promot Exch
 
1997
;
2
:
13
15
.
100
Fortenberry
JD
.
Alcohol, drugs, and STI/HIV risk among adolescents
.
AIDS Patient Care STDS
 
1998
;
12
:
783
786
.
101
Gehring
TM
Widmer
J
Kleiber
D
Steffen
R
.
Are preventive HIV interventions at airports effective?
J Travel Med
 
1998
;
5
:
205
209
.
102
Minichiello
V
Marino
R
Khan
MA
Browne
J
.
Alcohol and drug use in Australian male sex workers: its relationship to the safety outcome of the sex encounter
.
AIDS Care
 
2003
;
15
:
549
561
.
103
Apostolopoulos
Y
Sonmez
S
Yu
CH
.
HIV‐risk behaviours of American spring break vacationers: a case of situational disinhibition?
Int J STD AIDS
 
2002
;
13
:
733
743
.
104
Mewhinney
DM
Herold
ES
Maticka‐Tyndale
E
.
Sexual scripts and risk taking of Canadian university students on spring break in Daytona beach, Florida
.
Can J Hum Sex
 
1995
;
3
:
273
288
.
105
Moore
J
Beeker
C
Harrison
JS
, et al.
HIV risk behavior among Peace Corps Volunteers
.
AIDS
 
1995
;
9
:
795
799
.
106
Houweling
H
Coutinho
RA
.
Risk of HIV infection among Dutch expatriates in sub‐Saharan Africa
.
Int J STD AIDS
 
1991
;
2
:
252
257
.
107
De Graaf
R
Van Zessen
G
Houweling
H
, et al.
Sexual risk of HIV infection among expatriates posted in AIDS endemic areas
.
AIDS
 
1997
;
11
:
1173
1181
.
108
Bacaner
N
Stauffer
B
Boulware
DR
, et al.
Travel medicine considerations for North American immigrants visiting friends and relatives
.
JAMA
 
2004
;
291
:
2856
2864
.
109
Fulford
M
Keystone
JS
.
Health risks associated with visiting friends and relatives in developing countries
.
Curr Infect Dis Rep
 
2005
;
7
:
48
53
.
110
Wallace
D
.
WESTPAC, AIDS, and the Navy
.
Mil Med
 
1994
;
159
:
171
173
.
111
Anonymous
.
High condom quality essential to reduce HIV spread
.
Network
 
1988
;
10
:
6
7
.
112
Kramer
MA
Van Den Hoek
A
Coutinho
RA
Prins
M
.
Sexual risk behaviour among Surinamese and Antillean migrants travelling to their countries of origin
.
Sex Transm Infect
 
2005
;
81
:
508
510
.
113
Adams
EJ
Strike
PW
Green
AD
Masterton
RG
.
Sexually transmitted diseases in transient British forces in the tropics
.
Genitourin Med
 
1994
;
70
:
94
96
.
114
Shafer
MA
Boyer
CB
Shaffer
RA
, et al.
Correlates of sexually transmitted diseases in a young male deployed military population
.
Mil Med
 
2002
;
167
:
496
500
.
115
Hopperus Buma
AP
Veltink
RL
Van Ameijden
EJ
, et al.
Sexual behaviour and sexually transmitted diseases in Dutch marines and naval personnel on a United Nations mission in Cambodia
.
Genitourin Med
 
1995
;
71
:
172
175
.
116
Miller
N
Yeager
R
.
By virtue of their occupation, soldiers and sailors are at greater risk. Special report: the military
.
AIDS Anal Afr
 
1995
;
5
:
8
9
.
117
Vuksanovic
P
Goethe
WH
Burchard
HV
, et al.
Seamen and AIDS
.
Travel Med Int
 
1988
;
6
:
18
19
.
118
Pavli
P
Bayliss
GJ
Dent
OF
Lunzer
MR
.
The prevalence of serological markers for hepatitis B virus infection in Australian Naval personnel
.
Med J Aust
 
1989
;
151
:
71
,
74
75
.
119
Tiwari
VD
Talwar
S
Panvelkar
VV
Tutakne
MA
.
Wars and sexually transmitted diseases in the Indian Army
.
Indian J Sex Transm Dis
 
1992
;
13
:
80
82
.
120
Bond
MM
Yates
SW
.
Sexually transmitted disease screening and reporting practices in a military medical center
.
Mil Med
 
2000
;
165
:
470
472
.
121
Malone
JD
Hyams
KC
Hawkins
RE
, et al.
Risk factors for sexually‐transmitted diseases among deployed U.S. military personnel
.
Sex Transm Dis
 
1993
;
20
:
294
298
.
122
Abel
E
Adams
E
Stevenson
R
.
Sexual risk behaviour among female army recruits
.
Mil Med
 
1996
;
161
:
491
494
.
123
Hawkes
S
Hart
GJ
Bletsoe
E
, et al.
Risk behaviour and STI acquisition in genitourinary clinic attenders who have travelled
.
Genitourin Med
 
1995
;
71
:
351
354
.
124
Clift
SM
Forrest
SP
.
Factors associated with gay men’s sexual behaviours and risk on holiday
.
AIDS Care
 
1999
;
11
:
281
295
.
125
Salit
IE
Sano
M
Boggild
AK
Kain
KC
.
Travel patterns and risk behaviour of HIV‐positive people travelling internationally
.
CMAJ
 
2005
;
172
:
884
888
.
126
Fenton
KA
Imrie
J
.
Increasing rates of sexually transmitted diseases in homosexual men in Western Europe and the United States: why?
Infect Dis Clin North Am
 
2005
;
19
:
311
331
.
127
Hawkes
S
Hart
GJ
Johnson
AM
, et al.
Risk behaviour and HIV prevalence in international travellers
.
AIDS
 
1994
;
8
:
247
252
.
128
Thorpe
L
Ford
K
Fajans
P
Wirawan
DN
.
Correlates of condom use among female prostitutes and tourist clients in Bali, Indonesia
.
AIDS Care
 
1997
;
9
:
181
197
.
129
Abdullah
AS
Fielding
R
Hedley
AJ
Luk
YK
.
Risk factors for sexually transmitted diseases and casual sex among Chinese patients attending sexually transmitted disease clinics in Hong Kong
.
Sex Transm Dis
 
2002
;
29
:
360
365
.
130
Kleiber
D
Wilke
M
.
Sexual behaviour of German (sex) tourists
. Abstract WS‐D110‐2, 9th International Conference on AIDS, Berlin, Germany 1993.
131
Songkhla
MN
.
Quality control of condoms in Thailand: a case study
.
J Med Assoc Thai
 
1993
;
76
:
353
358
.
132
Deparis
X
Migliani
R
Merlin
M
.
Evidence of risk factors for condom breakage among French military personnel stationed overseas
.
Med Trop (Mars)
 
1999
;
59
:
266
270
.
133
Brisson
M
Boily
MC
Masse
BR
, et al.
Highlights of the sexual activity of the heterosexual population in the province of Quebec
.
Sex Transm Infect
 
1999
;
75
:
296
299
.
134
Leder
K
Weller
PF
Wilson
ME
.
Travel vaccines and elderly persons: review of vaccines available in the United States
.
Clin Infect Dis
 
2001
;
33
:
1553
1566
.
135
Wilson
MM
.
Sexually transmitted diseases
.
Clin Geriatr Med
 
2003
;
19
:
637
655
.
136
Van Kerkwijk
C
.
Sex tourism in Thailand
.
AIDS Soc
 
1992
;
4
:
6
7
.
137
Marrazzo
JM
.
Sexual tourism: implications for travelers and the destination culture
.
Infect Dis Clin North Am
 
2005
;
19
:
103
120
.
138
Puro
V
De Carli
G
Scognamiglio
P
, et al.
Risk of HIV and other blood‐borne infections in the cardiac setting: patient‐to‐provider and provider‐to‐patient transmission
.
Ann N Y Acad Sci
 
2001
;
946
:
291
309
.
139
Pinkerton
SD
Martin
JN
Roland
ME
, et al.
Cost‐effectiveness of postexposure prophylaxis after sexual or injection‐drug exposure to human immunodeficiency virus
.
Arch Intern Med
 
2004
;
164
:
46
54
.
140
Terrault
NA
.
Sexual activity as a risk factor for hepatitis C
.
Hepatology
 
2002
;
36
(5 Suppl 1):
S99
S105
.
141
O’Farrell
N
.
Transmission of HIV: genital ulceration, sexual behaviour, and circumcision
.
Lancet
 
1989
;
2
:
1157
.
142
Robinson
WS
.
Hepatitis B virus and hepatitis D virus
. In:
Mandel
G
,
Bennet
JE
,
Dolin
R
, eds.
Principles and practice of infectious diseases
. Philadelphia,
Churchill Livingstone
,
2000
:
1652
1684
.
143
Sparling
PF
Handsfield
HH
.
Neisseria gonorrheae
. In:
Mandel
G
,
Bennet
JE
,
Dolin
R
, eds.
Principles and practice of infectious diseases
. Philadelphia,
Churchill Livingstone
,
2000
:
2242
2258
.
144
Warner
L
Newman
DR
.,
Austin
HD
,
et al
.
Condom effectiveness for reducing transmission of gonorrhea and chlamydia: the importance of assessing partner infection status
.
Am J Epidemiol
2004
;
159
:
242
251
.
145
Larouze
B
Gaudebout
C
Mercier
E
, et al.
Infection with hepatitis A and B viruses in French volunteers working in tropical Africa
.
Am J Epidemiol
 
1987
;
126
:
31
37
.
146
Lange
WR
Frame
JD
.
High incidence of viral hepatitis among American missionaries in Africa
.
Am J Trop Med Hyg
 
1990
;
43
:
527
533
.
147
Arvidson
M
Hellberg
D
Mardh
PA
.
Sexually transmitted diseases in Swedish women with experience of casual sex with men of foreign nationalities within Sweden
.
Acta Obstet Gynecol Scand
 
1995
;
74
:
794
798
.
148
Hiltunen‐Back
E
Haikala
O
Koskela
P
, et al.
Epidemics due to imported syphilis in Finland
.
Sex Transm Dis
 
2002
;
29
:
746
751
.
149
Abdullah
AS
Fielding
R
Hedley
AJ
, et al.
Related reasons for not using condoms among the Hong Kong Chinese population: implications for HIV and STD prevention
.
Sex Transm Infect
 
2002
;
78
:
180
184
.
150
Gunn
RA
Harper
SL
Borntrager
DE
, et al.
Implementing a syphilis elimination and importation control strategy in a low‐incidence urban area: San Diego County, California, 1997‐1998
.
Am J Public Health
 
2000
;
90
:
1540
1544
.
151
Public Health Agency of Canada
.
Canadian guidelines on sexually transmitted infections 2006
(in press) Available at: http://www.phac-aspc.gc.ca/std-mts/sti_2006/sti-intro2006-e.html (2006 Aug 21).
152
CDC
.
Update: barrier protection against HIV infection and other sexually transmitted diseases
.
MMWR
 
1993
;
42
:
589
591
, 597.
153
Donovan
B
.
Sexually transmissible infections other than HIV
.
Lancet
 
2004
;
363
:
545
556
.
154
Gallo
MF
Grimes
DA
Schulz
KF
.
Non‐latex versus latex male condoms for contraception
.
Cochrane Database Syst Rev
 
2003
;
2
:CD003550.
155
Holmes
KK
Levine
R
Weaver
M
.
Effectiveness of condoms in preventing sexually transmitted infections
.
Bull World Health Organ
 
2004
;
82
:
454
461
.
156
Latka
M
.
Female‐initiated barrier methods for the prevention of STI/HIV: where are we now? Where should we go?
J Urban Health
 
2001
;
78
:
571
580
.
157
Macaluso
M
Lawson
ML
Hortin
G
, et al.
Efficacy of the female condom as a barrier to semen during intercourse
.
Am J Epidemiol
 
2003
;
157
:
289
297
.
158
Rosenberg
M
.
Contraception and STIs
.
IPPF Med Bull
 
1991
;
25
:
3
4
.
159
Wilkinson
D
Ramjee
G
Tholandi
M
Rutherford
G
.
Nonoxynol‐9 for preventing vaginal acquisition of sexually transmitted infections by women from men
.
Cochrane Database Syst Rev
 
2002
;
4
:CD003939.
160
Wilkinson
D
Tholandi
M
Ramjee
G
Rutherford
GW
.
Nonoxynol‐9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta‐analysis of randomised controlled trials including more than 5000 women
.
Lancet Infect Dis
 
2002
;
2
:
613
617
.
161
Kemper
C
.
Consider postexposure STI screening
.
AIDS Alert
 
2002
;
17
:
22
.
162
Various authors.
Canadian STI best practice guidelines
.
Can J Infect Dis Med Microbiol
 
2005
;
16
:Numbers 1 (
1
55
) and 2 (1–98).
163
Basuki
E
Wolffers
I
Deville
W
, et al.
Reasons for not using condoms among female sex workers in Indonesia
.
AIDS Educ Prev
 
2002
;
14
:
102
116
.
164
McKinzie
J
.
Sexually transmitted diseases
.
Emerg Med Clin North Am
 
2001
;
19
:
723
743
.
165
Cantu
M
Coppola
M
Lindner
AJ
.
Evaluation and management of the sexually assaulted woman
.
Emerg Med Clin North Am
 
2003
;
21
:
737
750
.
166
Dallabetta
G
.
HIV and STDS: how are they linked?
Afr Health
 
1994
;
17
:
19
20
.
167
Conard
LA
Gold
MA
.
Emergency contraceptive pills: a review of the recent literature
.
Curr Opin Obstet Gynecol
 
2004
;
16
:
389
395
.
168
Lynn
WA
Lightman
S
.
Syphilis and HIV: a dangerous combination
.
Lancet Infect Dis
 
2004
;
4
:
456
466
.
169
Kamenga
MC
De Cock
KM
St Louis
ME
, et al.
The impact of human immunodeficiency virus infection on pelvic inflammatory disease: a case‐control study in Abidjan, Ivory Coast
.
Am J Obstet Gynecol
 
1995
;
172
:
919
925
.
170
Bukusi
EA
Cohen
CR
Stevens
CE
, et al.
Effects of human immunodeficiency virus 1 infection on microbial origins of pelvic inflammatory disease and on efficacy of ambulatory oral therapy
.
Am J Obstet Gynecol
 
1999
;
181
:
1374
1381
.
171
Smith
KJ
Skelton
H
.
Molluscum contagiosum: recent advances in pathogenic mechanisms, and new therapies
.
Am J Clin Dermatol
 
2002
;
3
:
535
545
.
172
Khan
SA
.
Compulsory screening of immigrants for TB and HIV: broader focus is needed for immigration and health issues
.
BMJ
 
2004
;
328
:
897
.
173
Klein
A
.
Canadian news. Concerns raised about new immigration rules
.
Can HIV AIDS Policy Law Rev
 
2002
;
6
:
32
33
.
174
Calvet
HM
.
Sexually transmitted diseases other than human immunodeficiency virus infection in older adults
.
Clin Infect Dis
 
2003
;
36
:
609
614
.
175
Sanford
C
.
Pre‐travel advice: an overview
.
Prim Care
 
2002
;
29
:
767
785
.
176
De Serres
G
Duval
B
Shadmani
R
, et al.
Ineffectiveness of the current strategy to prevent hepatitis A in travelers
.
J Travel Med
 
2002
;
9
:
10
16
.
177
Fletcher
MA
.
Vaccine candidates in STD
.
Int J STD AIDS
 
2001
;
12
:
419
422
.
178
MacPherson
DW
.
Evidence‐based medicine
.
CMAJ
 
1995
;
152
:
201
204
.